1. Home
  2. HPI vs CRVS Comparison

HPI vs CRVS Comparison

Compare HPI & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HPI
  • CRVS
  • Stock Information
  • Founded
  • HPI 2002
  • CRVS 2014
  • Country
  • HPI United States
  • CRVS United States
  • Employees
  • HPI N/A
  • CRVS N/A
  • Industry
  • HPI Trusts Except Educational Religious and Charitable
  • CRVS Biotechnology: Pharmaceutical Preparations
  • Sector
  • HPI Finance
  • CRVS Health Care
  • Exchange
  • HPI Nasdaq
  • CRVS Nasdaq
  • Market Cap
  • HPI 421.3M
  • CRVS 305.4M
  • IPO Year
  • HPI N/A
  • CRVS 2016
  • Fundamental
  • Price
  • HPI $16.23
  • CRVS $4.03
  • Analyst Decision
  • HPI
  • CRVS Strong Buy
  • Analyst Count
  • HPI 0
  • CRVS 4
  • Target Price
  • HPI N/A
  • CRVS $15.00
  • AVG Volume (30 Days)
  • HPI 64.7K
  • CRVS 1.2M
  • Earning Date
  • HPI 01-01-0001
  • CRVS 08-05-2025
  • Dividend Yield
  • HPI 8.97%
  • CRVS N/A
  • EPS Growth
  • HPI N/A
  • CRVS N/A
  • EPS
  • HPI N/A
  • CRVS N/A
  • Revenue
  • HPI N/A
  • CRVS N/A
  • Revenue This Year
  • HPI N/A
  • CRVS N/A
  • Revenue Next Year
  • HPI N/A
  • CRVS N/A
  • P/E Ratio
  • HPI N/A
  • CRVS N/A
  • Revenue Growth
  • HPI N/A
  • CRVS N/A
  • 52 Week Low
  • HPI $12.85
  • CRVS $1.75
  • 52 Week High
  • HPI $16.83
  • CRVS $10.00
  • Technical
  • Relative Strength Index (RSI)
  • HPI 64.06
  • CRVS 50.43
  • Support Level
  • HPI $15.86
  • CRVS $3.55
  • Resistance Level
  • HPI $16.00
  • CRVS $4.09
  • Average True Range (ATR)
  • HPI 0.14
  • CRVS 0.31
  • MACD
  • HPI 0.03
  • CRVS -0.03
  • Stochastic Oscillator
  • HPI 96.61
  • CRVS 49.14

About HPI John Hancock Preferred Income Fund of Beneficial Interest

John Hancock Preferred Income Fund is a closed-end, diversified management investment company. Its primary investment objective is to provide a high level of current income consistent with preservation of capital. The fund's secondary investment objective is to provide growth of capital to the extent consistent with its primary investment objective. It seeks to achieve its investment objectives by investing in securities that may be undervalued relative to similar securities in the marketplace. The fund's principal investment strategies include investing a majority of its assets in preferred stocks and other preferred securities. Its portfolio composition consists of U.S preferred securities, common stocks, foreign preferred securities, corporate bonds, and short-term investments.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Share on Social Networks: